BioNxt Solutions Strengthens Commercial Hand with Unified European Patent

BioNxt's European patent strengthens its commercial path for its sublingual film drug delivery platform, boosting investor confidence and streamlining licensing talks.

The path to commercialization for BioNxt Solutions is becoming clearer, bolstered by a significant legal milestone. The company has successfully registered a European patent with unitary effect for its core sublingual oral thin film (ODF) platform, a move that fundamentally strengthens its position for future licensing deals. This patent, numbered EP 4539857, provides centralized protection across 18 EU member states, including major markets like Germany, France, Italy, and the Netherlands.

This unified legal framework, registered by the European Patent Office on March 31, 2026, with a retroactive effect from March 11, eliminates the need for costly and administratively burdensome national validations in each country. The patent’s priority date is June 15, 2022, ensuring protection extends well into the 2040s. For BioNxt, this is more than just intellectual property security; it’s a strategic lever to streamline negotiations for regional licensing and co-development partnerships for its lead candidate, BNT23001.

The protected technology involves embedding a Cladribin-cyclodextrin complex into a hydrophilic polymer matrix for transmucosal delivery. While initially targeted at multiple sclerosis (MS), the platform’s potential extends to other neurological and autoimmune conditions such as lupus nephritis, myasthenia gravis, and neuromyelitis optica spectrum disorders.

Investors responded positively to this strategic progress. The company’s share price climbed 8.71 percent, reaching EUR 0.34. This uptick reflects growing confidence in BioNxt’s transition from a pure developer to a commercial-stage biotech firm.

On the clinical front, the company is preparing for a pivotal human bioavailability study. The clinical pathway is considered relatively streamlined because the active ingredient, Cladribin, is already an approved drug. The upcoming study will focus on demonstrating the bioavailability of the new ODF formulation compared to existing oral tablets, building on promising preclinical data that showed comparable systemic exposure to the reference product Mavenclad without treatment-related side effects from repeated sublingual dosing. BioNxt is collaborating with a specialized clinical research organization to finalize the study design and meet regulatory requirements.

The commercial strategy is decidedly global. Alongside the secured European and Eurasian footprint—the latter covered by a recently signed letter of intent for a market of over 200 million people—BioNxt is pursuing an accelerated examination process in the United States. This effort aims to secure patent protection there promptly and broaden the platform's focus to additional disease areas.

With the geographic framework for potential licensing now clearly staked out in key regions, the immediate next milestone is the successful execution of the upcoming human bioavailability study, a critical step toward the company's goal of market readiness.